<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01271101</url>
  </required_header>
  <id_info>
    <org_study_id>EASY-CHINA</org_study_id>
    <nct_id>NCT01271101</nct_id>
  </id_info>
  <brief_title>The Efficacy and Safety of Anticoagulation in Chinese Patients With Non-ST Segment Elevation Acute Coronary Syndrome</brief_title>
  <acronym>EASY-CHINA</acronym>
  <official_title>The Efficacy and Safety of Anticoagulation in Chinese Patients With Non-ST Segment Elevation Acute Coronary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the EASY-CHINA Registry is to describe the clinical epidemiology of&#xD;
      Chinese patients with NSTE-ACS, to evaluate their current anticoagulation management in&#xD;
      China, and the resources used for it.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Non-ST-elevated acute coronary syndromes (NSTE-ACS)are the leading cause of emergency medical&#xD;
      care in the USA. In China, these syndromes have also become the major causes of morbidity and&#xD;
      mortality and account for several thousands of death and hospitalizations annually.&#xD;
      Anti-platelet drugs, anticoagulants and intervention therapy for high-risk NSTE-ACS patients&#xD;
      may increase bleeding events while reducing ischemic coronary events. There are some&#xD;
      evidences supporting the association between hemorrhagic complications and short- and&#xD;
      long-term mortality. Therefore, future advances in antithrombotic therapy for NSTE-ACS need&#xD;
      to focus on reducing ischemic event rates without increasing hemorrhagic complication rates.&#xD;
      In this general framework, there is the need for an appropriate adoption of the available&#xD;
      evidences concerning therapeutic strategies, specifically the use of the different&#xD;
      antithrombotic strategies, in real world patients in order to further improve their&#xD;
      outcomes.The primary objective of this study is to describe the clinical epidemiology of&#xD;
      Chinese patients with NSTE-ACS, and to evaluate their current management in China. This study&#xD;
      will be an observational survey, thus zero interference is emphasized throughout it. No&#xD;
      randomization, blinding or special treatment will be assigned for the subjects. Issues&#xD;
      concerning the care of subjects are completely left to the discretion of investigators in&#xD;
      order to collect the real-world information about the pharmacological treatments for NSTE-ACS&#xD;
      patients in china.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">August 2011</completion_date>
  <primary_completion_date type="Anticipated">March 2011</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>the composite of death, MI, refractory ischemia, or stroke and the major bleeding</measure>
    <time_frame>9 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>the composite of death, MI, refractory ischemia, or stroke</measure>
    <time_frame>30 days</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">1800</enrollment>
  <condition>Acute Coronary Syndrome</condition>
  <arm_group>
    <arm_group_label>anticoagulant</arm_group_label>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Chinese patients with non-ST-elevated acute coronary syndrome&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  with symptoms of UA or MI without persistent ST elevation and at least 1 of the&#xD;
             following additional criterias: 1)troponin T or I or CK-MB above the upper limit of&#xD;
             normal,2)electrocardiogram (ECG) changes compatible with ischemia (ie, ST depression&#xD;
             at least 1mm in 2 contiguous leads or T-wave inversion &gt;3 mm),3)any dynamic ST shift&#xD;
             or transient ST elevation&#xD;
&#xD;
          -  Must be willing to signed informed consent&#xD;
&#xD;
          -  age from 21-80 years&#xD;
&#xD;
          -  without pregnancy or under contraception&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age&lt;20 or &gt;80 years&#xD;
&#xD;
          -  any contraindication to anticoagulant&#xD;
&#xD;
          -  hemorrhagic stroke within 12 months&#xD;
&#xD;
          -  indication for anticoagulation other than ACS&#xD;
&#xD;
          -  prior enrollment in anticoagulants trials in ACS&#xD;
&#xD;
          -  revascularization procedure performed for the qualifying event in one month&#xD;
&#xD;
          -  severe renal insufficiency (ie,serum creatinine&gt;=3 mg/dL or 265umol/L)&#xD;
&#xD;
          -  pregnancy or breast-feeding women&#xD;
&#xD;
          -  life expectancy&lt;6 months&#xD;
&#xD;
          -  enrollment in other medicine trials in 3 months&#xD;
&#xD;
          -  with mental illness or uncooperative&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jinming Yu, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>School of Public Health, Fudan University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>School of Public Health, Fudan University</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinming Yu, Doctor</last_name>
      <phone>+86-21-54237868</phone>
      <email>jmy@fudan.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2010</verification_date>
  <study_first_submitted>January 5, 2011</study_first_submitted>
  <study_first_submitted_qc>January 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2011</study_first_posted>
  <last_update_submitted>January 5, 2011</last_update_submitted>
  <last_update_submitted_qc>January 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jinming Yu</name_title>
    <organization>School of Public Health, Fudan University</organization>
  </responsible_party>
  <keyword>Non-ST-elevated acute coronary syndromes (NSTE-ACS)</keyword>
  <keyword>anticoagulation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Coronary Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

